03 Dec 2019 - EQT Holdings Limited (ASX:EQT) Managing Director, Mick O'Brien talks FY19 results, market conditions, contribution from recent acquisitions and outlook for 1H20.
03 Dec 2019 - Synertec Corporation Limited (ASX:SOP) Managing Director, Michael Carroll & CFO, David Harris talk FY19 results, market conditions and the outlook for specialist engineering and compliance services.
2 Dec 2019 - DomaCom Limited (ASX:DCL) CEO Arthur Naoumidis talks about a year of significant progress with regulators, the company's capital raising to accelerate marketing and FUM and the tailwinds making fractional investment attractive.
29 Nov 2019 - Xplore Wealth Limited (ASX:XPL) CEO, Michael Wright, talks about the benefits of the company's non-aligned platform following the Hayne Royal Commission and key priorities for FY20.
25 Nov 2019 - Lepidico (ASX:LPD) Managing Director, Joe Walsh provides an update on drill results from its recently acquired Rubicon and Helikon deposits in Namibia, L-Max Pilot Plant trial results and outlook.
21 Nov 2019 - Alpha HPA (ASX:A4N) Managing Director, Rimas Kairaitis provides an update on the company's High Purity Aluminum (HPA) processing technology, pilot plant program and project economics.
20 Nov 2019 - Ausbil Investment Management Chief Investment Officer, Paul Xiradis and Ausbil Head of ESG Research, Måns Carlsson-Sweeny, provide an update on the Ausbil Active Sustainable Equity fund’s performance, talk about what the fund looks for in businesses that fit the description of "sustainable", and discuss how these characteristics provide long-term above-market returns.
19 Nov 2019 - Redcape Hotel Group Limited (ASX:RDC) CEO, Dan Brady discusses FY19 results, company strategy and creating pub venues that become the hub of local communities.
01 Nov 2019 - IVE Group Limited (ASX:IGL) Executive Chairman, Geoff Selig talks about FY19 results, trends strategy and FY20 outlook.
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
